Breast Cancer | Specialty

OncLive News Network On Location: In Chicago Monday, June 4

June 2nd 2018

OncLive News Network On Location: In Chicago Sunday, June 3

June 2nd 2018

OncLive News Network On Location: In Chicago Saturday, June 2

June 2nd 2018

OncLive News Network On Location: In Chicago Friday, June 1

June 2nd 2018

Dr. Page on Hormone-Directed Strategies in Triple-Negative Breast Cancer

May 31st 2018

David B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).

Dr. Kubicky on the Optimal Use of Radiation in Patients With Breast Cancer

May 29th 2018

Charlotte Kubicky, MD, PhD, associate professor of radiation medicine, School of Medicine, medical director, Tuality Oregon Health and Science Cancer Center, Oregon Health and Science University, discusses the optimal use of radiation in the treatment of patients with breast cancer.

Expert Recaps Adjuvant Advancements in HER2+ Breast Cancer

May 24th 2018

Haythem Y. Ali, MD, discusses adjuvant advances in HER2-postitive breast cancer and emerging agents in the field.

Dr. Jhaveri on Acquired Resistance to CDK 4/6 Inhibitors in Breast Cancer

May 24th 2018

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.

Dr. Newman on Advances in Axillary Surgery in Breast Cancer

May 22nd 2018

Lisa A. Newman, MD, director, Breast Oncology Program, Henry Ford Cancer Institute, discusses advances in axillary surgery for the treatment of patients with node-positive breast cancer.

Dr. Simon on Genomic Assays for Patients With Breast Cancer

May 22nd 2018

Michael Simon, MD, MPH, medical oncologist, Karmanos Cancer Institute, discusses genomic assays for patients with breast cancer.

Dr. Walker on the Use of Radiation Therapy in Patients With Breast Cancer

May 22nd 2018

Eleanor M. Walker, MD, senior staff physician, division director, Breast Services in the Department of Radiation Oncology, Henry Ford Cancer Institute, discusses the use of radiation therapy in patients with breast cancer.

Experts Discuss Frontline CDK4/6 Inhibitors in ER+ Breast Cancer

May 19th 2018

Dennis J. Slamon, MD, PhD, and Sara A. Hurvitz, MD, discuss the impact of CDK4/6 inhibitors in ER-positive breast cancer.

Expert Addresses Optimal Use of Endocrine Therapy in HR+ Breast Cancer

May 10th 2018

Rena D. Callahan, MD, discusses controversies in the management of early-stage HR-positive breast cancer and neoadjuvant trial designs for these patients.

Link Between Diet and Breast Cancer Recurrence Risk Still Unknown

May 9th 2018

Aashini Master, DO, discusses efforts to integrate nutrition and health into breast cancer survivorship.

Dr. Master on the Mediterranean Diet in Relation to Breast Cancer Risk

May 8th 2018

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.

Expert Explains State of Surgery in Nonmetastatic Breast Cancer

May 7th 2018

Maggie DiNome, MD, discusses the evolution of surgical approaches in patients with early-stage breast cancer.

HER2+ Breast Cancer Outlook Improved, But More Work Remains

May 5th 2018

Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.

Dr. Chagpar Discusses Benefit of Primary Tumor Surgery in Breast Cancer

May 3rd 2018

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses the potential benefit of primary tumor surgery for patients with breast cancer.

Postoperative Radiation in Breast Cancer Now a Personalized Process

May 2nd 2018

Susan A. McCloskey, MD, discusses the use of postoperative radiation in patients with breast cancer.

CDK4/6 Inhibition Refined in HR+ Breast Cancer, as Novel Combos Emerge

May 1st 2018

Sara Hurvitz, MD, shares insight on the 3 CDK4/6 inhibitors approved in HR-positive breast cancer, and looks toward the future of these agents, which will likely include combination strategies.